Pleiotropic effects of micronised fenofibrate in patients with combined hyperlipidemia;Plejotropowe działanie fenofibratu mikronizowanego u chorych z hiperlipidemia̧ mieszana̧

Polski Merkuriusz Lekarski

Volumn 13, Issue 78, 2002, Pages 465-469

  Okopień, Bogusław ^a   Cwalina, Łukasz ^a   Haberka, Maciej ^a   Kowalski, Jan ^a   Zieliński, Marek ^a   Szwed, Zygmunt ^a   Kalina, Zbigniew ^a   Herman, Zbigniew S ^a  

^a NONE

Author keywords

Combined hyperlipidemia; Fibrates; Fibrinogen; Plasminogen activator inhibitor 1; Tumor necrosis factor alpha

Indexed keywords

CHOLESTEROL; CYTOKINE; FENOFIBRATE; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD CLOTTING; BLOOD VESSEL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPID BLOOD LEVEL; MALE; MICRONIZATION; MONOCYTE; PERIPHERAL CIRCULATION; PLEIOTROPY; STATISTICAL SIGNIFICANCE;

EID: 0036970773     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Abi-Younes S. i wsp.: The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res., 2000, 86, 131-8.
2. Arroyo L., Lee R.: Mechanism of plaque rupture: mechanical and biologic interactions. Cardiovasc. Res., 1999, 41, 369-75.
3. Arts J. i wsp.: Studies on the mechanism on fibrate inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. Arterioscler. Thromb. Vasc. Biol., 1996, 17, 26-32.
4. Aviram M. i wsp.: Atorvastatin and gemfibrosil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis, 1998, 138, 271-5.
5. Banfi C. i wsp.: Very low-density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ. Res., 1999, 85, 208-17.
6. Bröijersen A. i wsp.: Gemfibrozil treatment of combined hyperlipoproteinemia. Arterioscler. Thromb. Vasc. Biol., 1996, 16, 511-16.
7. Cirino G. i wsp.: Inflammation-coagulation network, are serine protease receptors the knot? Trends Pharmacol. Sci., 2000, 21, 170-2.
8. Corton J. i wsp.: Down-regulation of cytochrome P420 family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. Mol. Pharmacol., 1998, 54, 463-73.
9. Cushman M. i wsp.: Fibrinolytic activation markers predict myocardial infarcion in the elderly. The Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol., 1999, 19(3), 493-8.
10. Dong Z. i wsp.: Combined role of P- and E-selectins in atherosclerosis. J. Clin. Invest., 1998, 102, 145-52.
11. Durrington P.N. i wsp.: Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis, 1998, 138, 217-225.
12. Fuster V. i wsp.: Acute coronary syndromes biology. Lancet, 1999, 353 suppl 2, sII5-sII9.
13. Goetzl E., Lynch K.: Lysophospholipids and eicosanoids in biology and pathophysiology. Ann. NY Acad. Sci., 2000, 905, 1-357.
14. Gryglewski R.: Interactions between endothelial secretogogues. Ann. Med., 1995, 27, 421-7.
15. Gryglewski R. i wsp.: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature, 1986, 320, 454-6.
16. Hiraga S. i wsp.: Modulation of collagen synthesis by tumor necrosis factor alfa in cultured vascular smooth muscle cells. Life Sci., 2000, 66, 235-44.
17. Juhan-Vague I. i wsp.: Fibrinolytic function and coronary risk. Curr. Card. Rep., 1999, 1(2) 119, 124.
18. Kannel W.B. i wsp.: Fibrinogen and risk of cardiovascular disease. The Framingham Study. Jama, 1987, 258, 1183-6.
19. Knight C. i wsp.: Collagen platelet interaction Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activisation by collagen. Cardiovasc. Res., 1999, 41, 450-7.
20. Kockx M. i wsp.: Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb. Haem., 1997, 78(4), 1167-72.
21. Kockx M. i wsp.: Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes-role of the peroxisome proliferator-activated receptor-alfa. Thromb. Haemost., 1998, 80(6), 942-8.
22. Lamarche B. i wsp.: Fasting insulin and apolipoprotein B levels and law density lipoprotein particle size as a risk factors for ischemic heart disease. JAMA, 1998, 279, 1955-61.
23. Laufs U. i wsp.: Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation, 1998, 97, 1129-35.
24. Loskutoff D., Samad F.: The adipocyte and hemostatic balance in obesity. Studies of PAI-1. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 1-6.
25. Mach F. i wsp.: Reduction of atherosclerosis in mice by inhibition of CD 40 signalling. Nature, 1998, 394, 200-3.
26. Mach F. i wsp.: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD 40, induction of collagenase, stromelysin and tissue factor. Circulation, 1997, 96, 396-9.
27. Marx N. i wsp.: PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99, 3125-31.
28. Rosenson R., Lowe G.: Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis, 1998, 140, 271-80.
29. Ross R.: Atherosclerosis - an inflammatory disease. N. Engl. J. Med., 1999, 340, 115-26.
30. Rossi G. i wsp.: Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation, 1999, 99, 1147-55.
31. Saren P. i wsp.: TNF-α and II-1β selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol., 1996, 157, 4159-65.
32. Schoojans K. i wsp.: Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J. Lipid. Res., 1996, 37, 907-25.
33. Shepherd J.: The fibrates clinical practice, focus on micronised fenofibrate. Atherosclerosis, 1994, 110 suppl., S55-S63.
34. Steals B. i wsp.: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998, 98, 2088-93.
35. Sweetnam P. i wsp.: Fibrinogen, viscosity, and the 10-year incidence of ischaemic heart disease. Eur. Heart J., 1996, 17, 1814-20.
36. Thogersen A.M. i wsp.: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarcion in both men and women, evidence for fibrinolytic system as an indepedent primary risk factor. Circulation, 1998, 21, 2241-7.
37. Toss H. i wsp.: Prognostic influence of incraased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation, 1997, 96, 4204-10.
38. Van der Wal A., Becker A.: Atherosclerotic plaque rupture-pathologic basis of plaque stability and instability. Cardiovasc. Res., 1999, 41, 334-44.
39. Wiman B. i wsp.: Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler. Thromb. Vasc. Biol., 2000, 20(8), 2019-23.
40. Woodward M. i wsp.: Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur. Heart J., 1998, 19(1), 55-62.
41. Yoshida H. i wsp.: Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein, a randomized, double-blind, placebo-controlled study. Atherosclerosis, 1998, 139, 179-87.